Profil
Mark H.
Pavao was the founder of R-Pharm US LLC, founded in 2014, where the titles held included President, Chief Executive Officer & Director.
Current jobs include Independent Director at Coya Therapeutics, Inc. starting in 2026, and Chief Commercial Officer at BioXcel Therapeutics, Inc. starting in 2026.
Former job includes Senior Vice President-Sales & Marketing at NitroMed, Inc.
Aktive Positionen von Mark Pavao
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOXCEL THERAPEUTICS, INC. | Corporate Officer/Principal | 12.01.2026 |
| COYA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.04.2026 |
Ehemalige bekannte Positionen von Mark Pavao
| Unternehmen | Position | Ende |
|---|---|---|
R-Pharm US LLC
R-Pharm US LLC Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of medicines to treat cancer | Gründer | - |
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies pharmaceuticals | Vertrieb & Marketing | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies pharmaceuticals | Health Technology |
R-Pharm US LLC
R-Pharm US LLC Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of medicines to treat cancer | Health Technology |
BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops transformative medicines in neuroscience and immuno-oncology | Health Technology |
Coya Therapeutics, Inc.
Coya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that focuses on research and development of therapies to enhance the function of regulatory T cells | Health Technology |
















